{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:29:18Z","timestamp":1789540158793,"version":"build-2803163510"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["95106"],"award-info":[{"award-number":["95106"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["90729"],"award-info":[{"award-number":["90729"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["PACTR201105000291300"],"award-info":[{"award-number":["PACTR201105000291300"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Rifampin is a key sterilizing drug in the treatment of tuberculosis (TB). It induces its own metabolism, but neither the onset nor the extent of autoinduction has been adequately described. Currently, the World Health Organization recommends a rifampin dose of 8 to 12 mg\/kg of body weight, which is believed to be suboptimal, and higher doses may potentially improve treatment outcomes. However, a nonlinear increase in exposure may be observed because of saturation of hepatic extraction and hence this should be taken into consideration when a dose increase is implemented. Intensive pharmacokinetic (PK) data from 61 HIV-TB-coinfected patients in South Africa were collected at four visits, on days 1, 8, 15, and 29, after initiation of treatment. Data were analyzed by population nonlinear mixed-effects modeling. Rifampin PKs were best described by using a transit compartment absorption and a well-stirred liver model with saturation of hepatic extraction, including a first-pass effect. Autoinduction was characterized by using an exponential-maturation model: hepatic clearance almost doubled from the baseline to steady state, with a half-life of around 4.5 days. The model predicts that increases in the dose of rifampin result in more-than-linear drug exposure increases as measured by the 24-h area under the concentration-time curve. Simulations with doses of up to 35 mg\/kg produced results closely in line with those of clinical trials.<\/jats:p>","DOI":"10.1128\/aac.01830-15","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T23:09:28Z","timestamp":1447110568000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":80,"title":["Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction"],"prefix":"10.1128","volume":"60","author":[{"given":"Maxwell T.","family":"Chirehwa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Rustomjee","sequence":"additional","affiliation":[{"name":"Strategic Health Innovation Partnerships (SHIP), South African Medical Research Council, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuli","family":"Mthiyane","sequence":"additional","affiliation":[{"name":"TB Research Unit: Clinical and Biomedical, South African Medical Research Council, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Onyebujoh","sequence":"additional","affiliation":[{"name":"Intercountry Support Team for East and Southern Africa, World Health Organization Regional Office for Africa, Harare, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.5.1520"},{"key":"e_1_3_3_4_2","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart KR","year":"2011","unstructured":"Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. 2011. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 15:305\u2013316.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1210OC"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01733779"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-3"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-07"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05526-11"},{"key":"e_1_3_3_14_2","volume-title":"Treatment of tuberculosis: guidelines for national programmes","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd edition. WHO\/CDS\/TB\/2003.313. World Health Organization, Geneva, Switzerland.","edition":"3"},{"key":"e_1_3_3_15_2","volume-title":"NONMEM users guides (1989\u20132009)","author":"Beal S","year":"2009","unstructured":"Beal S, Sheiner L, Boeckmann A, Bauer R. 2009. NONMEM users guides (1989\u20132009). ICON Development Solutions, Ellicott City, MD."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_3_17_2","volume-title":"R: a language and environment for statistical computing, version 3.1.2","author":"R Core Team","year":"2014","unstructured":"R Core Team. 2014. R: a language and environment for statistical computing, version 3.1.2. R Core Team, Vienna, Austria."},{"key":"e_1_3_3_18_2","volume-title":"RStudio: integrated development environment for R, version 0.98.1091","author":"RStudio","year":"2014","unstructured":"RStudio. 2014. RStudio: integrated development environment for R, version 0.98.1091. RStudio, Boston, MA."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02321.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_3_3_21_2","volume-title":"3rd International Workshop on Clinical Pharmacology of TB Drugs","author":"Denti P","year":"2010","unstructured":"Denti P, Smythe W, Simonsson USH, Rustomjee R, Onyebujoh P, Smith P, McIlleron H. 2010. A population pharmacokinetic model for rifampicin auto-induction. 3rd International Workshop on Clinical Pharmacology of TB Drugs, Boston, MA. http:\/\/regist2.virology-education.com\/3tb\/docs\/12_denti.pdf."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_3_26_2","first-page":"15","volume-title":"6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs","author":"Chigutsa E","year":"2013","unstructured":"Chigutsa E, Pasipanodya JG, Visser ME, Sirgel FA, Gumbo T, McIlleron H. 2013. Multivariate adaptive regression splines analysis of the effect of drug concentration and MIC on sterilizing activity in patients on multidrug therapy, abstr 14, p 15. 6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Denver, CO. http:\/\/regist2.virology-education.com\/abstractbook\/programbook_6thTB-PK.pdf."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561755"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000220750"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S428"},{"key":"e_1_3_3_31_2","first-page":"70","article-title":"Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers","volume":"5","author":"Pargal A","year":"2001","unstructured":"Pargal A, Rani S. 2001. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis 5:70\u201379.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/5.4.447"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-06"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-13"},{"key":"e_1_3_3_35_2","first-page":"944","article-title":"Dosage of antituberculous drugs in obese patients","volume":"131","author":"Geiseler PJ","year":"1985","unstructured":"Geiseler PJ, Manis RD, Maddux MS. 1985. Dosage of antituberculous drugs in obese patients. Am Rev Respir Dis 131:944\u2013946.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_3_37_2","first-page":"879","article-title":"U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis","volume":"119","author":"Long MW","year":"1979","unstructured":"Long MW, Snider DE, Farer LS. 1979. U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 119:879\u2013894.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(97)90016-2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.10.5831-5844.2003"}],"updated-by":[{"DOI":"10.1128\/aac.00483-16","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01830-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01830-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:29:54Z","timestamp":1645457394000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01830-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1128\/AAC.01830-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01830-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}